Evidence map›Paper›PMID 34352486›Full record

ReviewCurrent opinion in pharmacology2021

Systems modeling of metabolic dysregulation in neurodegenerative diseases.

Priyanka Baloni, Cory C Funk, Ben Readhead, Nathan D Price

Abstract readReview
In one paragraph

Review in Current opinion in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Priyanka BaloniInstitute for Systems Biology, Seattle, WA, USA.
Cory C FunkInstitute for Systems Biology, Seattle, WA, USA.
Ben ReadheadOnegevity, a Division of Thorne HealthTech, New York, NY, USA; Arizona State University-Banner Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ, USA.
Nathan D PriceInstitute for Systems Biology, Seattle, WA, USA; Onegevity, a Division of Thorne HealthTech, New York, NY, USA. Electronic address: nathan.price@isbscience.org.

Funding

Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.U01AG046139 · NIA · UNIVERSITY OF FLORIDA · PI ERTEKIN-TANER, NILUFER, FUNK, CORY · 2013 to 2022
$24.6M
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-ADU01AG061359 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2018 to 2022
$10.0M
Identification of the genetic and transcriptomic networks of cognitive and neuropathological resilience to Alzheimer's Disease associated virusesU01AG061835 · NIA · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI READHEAD, BENJAMIN · 2018 to 2022
$6.5M
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in ADR01AG061796 · NIA · MAYO CLINIC JACKSONVILLE · PI ERTEKIN-TANER, NILUFER · 2018 to 2022
$5.7M
SYSTEMATIC DRUG REPURPOSING TARGETING IMMUNE ACTIVATION NETWORKS IN ALZHEIMER'S DISEASE (AD)RF1AG059319 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EHRLICH, MICHELLE E, GANDY, SAMUEL E. · 2018 to 2018
$4.2M
Integrated understanding of complex viral network biology in Alzheimer's DiseaseRF1AG058469 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EHRLICH, MICHELLE E, GANDY, SAMUEL E. · 2019 to 2019
$4.1M
Metabolic Network Analysis of Biochemical Trajectories in Alzheimer's DiseaseRF1AG057452 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2017 to 2017
$3.5M
Modulation of Alzheimers disease by Herpes simplex virus infection R01AG062514 · NIA · UNIVERSITY OF WASHINGTON · PI DARVAS, MARTIN C, FUNK, CORY · 2019 to 2023
$2.7M
Investigation of chromosomally integrated Human Herpesvirus 6 as a risk factor for Alzheimer's diseaseR21AG063068 · NIA · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI READHEAD, BENJAMIN · 2019 to 2020
$467k
NIA NIH HHS R01 AG061796NIA NIH HHS R01 AG062514NIA NIH HHS R21 AG063068NIA NIH HHS RF1 AG057452NIA NIH HHS RF1 AG058469NIA NIH HHS RF1 AG059319NIA NIH HHS U01 AG046139NIA NIH HHS U01 AG061359NIA NIH HHS U01 AG061835
6 · The paper itself

Abstract

Neurodegenerative diseases (NDDs) encompass a wide range of conditions that arise owing to progressive degeneration and the ultimate loss of nerve cells in the brain and peripheral nervous system. NDDs such as Alzheimer's, Parkinson's, and Huntington's diseases negatively impact both length and quality of life, due to lack of effective disease-modifying treatments. Herein, we review the use of genome-scale metabolic models, network-based approaches, and integration with multiomics data to identify key biological processes that characterize NDDs. We describe powerful systems biology approaches for modeling NDD pathophysiology by leveraging in silico models that are informed by patient-derived multiomics data. These approaches can enable mechanistic insights into NDD-specific metabolic dysregulations that can be leveraged to identify potential metabolic markers of disease and predisease states.

Indexed as

Huntington DiseaseNeurodegenerative DiseasesBrainHumansQuality of LifeSystems BiologyNeurodegenerative diseases, Metabolic modeling, Multiomics analysis, Network approaches

Identifiers

PMID34352486
PMCPMC8511060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.